Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban after recent acute coronary syndrome
NL-OMON33722Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rivaroxaban in acute coronary syndrome (ACS) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Primary efficacy endpoint. Started Jan 2009; status: active, not recruiting.
02
Drugs
rivaroxaban
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NL-OMON33722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33722.